| Date Filed | Type | Description |
| 09/29/2023 |
SC 13G
| Deep Track Capital, LP reports a 6.1% stake in HilleVax, Inc. |
| 09/27/2023 |
SC 13D/A
| Frazier Life Sciences Public Fund, L.P. reports a 20.2% stake in HilleVax, Inc. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
4
| Chu Shelley (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
| 06/09/2023 |
4
| Cocero Nanette (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 11,000 options
@ $17.94, valued at
$197.3k
|
|
| 06/09/2023 |
4
| Gerberding Julie L. (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
| 06/09/2023 |
4
| Sepulveda Jaime (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
| 06/09/2023 |
4
| HILLEMAN JERYL L (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
| 06/09/2023 |
4
| Heron Patrick J (10% Owner) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
| 05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
4
| Cocero Nanette (Director) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Granted 34,000 options to buy
@ $14.2, valued at
$482.8k
|
|
| 05/10/2023 |
3
| Cocero Nanette (Director) has filed a Form 3 on HilleVax, Inc. |
| 05/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/17/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.3% stake in HILLEVAX, INC. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 8.1% stake in HilleVax, Inc. |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
3
| Maltbie Shane (CFO) has filed a Form 3 on HilleVax, Inc. |
| 01/09/2023 |
8-K
| Investor presentation |
| 12/01/2022 |
4
| TAKEDA PHARMACEUTICAL CO LTD (10% Owner) has filed a Form 4 on HilleVax, Inc.|
Txns:
| Exercised (in-or-at-the-money) 5,883,500 shares
@ $0
Exercised (in-or-at-the-money) 5,883,500 warrants
@ $0.0001, valued at
$588.4 |
|
|